Which has higher valuation & earnings, STIM or INMD?

InMode has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $149.16M 1.47 -$39M -$0.44 N/A InMode $370.49M 2.20 $93.83M $1.23 11.54

Is STIM or INMD more profitable?

InMode has a net margin of 20.69% compared to Neuronetics' net margin of -19.62%. InMode's return on equity of 11.99% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% InMode 20.69% 11.99% 10.60%

Does the media prefer STIM or INMD?

In the previous week, Neuronetics and Neuronetics both had 2 articles in the media. InMode's average media sentiment score of 0.31 beat Neuronetics' score of 0.00 indicating that InMode is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InMode 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AVR or STIM?

In the previous week, Anteris Technologies Global had 1 more articles in the media than Neuronetics. MarketBeat recorded 3 mentions for Anteris Technologies Global and 2 mentions for Neuronetics. Anteris Technologies Global's average media sentiment score of 0.70 beat Neuronetics' score of 0.00 indicating that Anteris Technologies Global is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anteris Technologies Global 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuronetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, SIBN or STIM?

SiBone has higher revenue and earnings than Neuronetics. SiBone is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $213.60M 3.86 -$18.90M -$0.34 N/A Neuronetics $149.16M 1.47 -$39M -$0.44 N/A

Is SIBN or STIM more profitable?

SiBone has a net margin of -6.85% compared to Neuronetics' net margin of -19.62%. SiBone's return on equity of -8.23% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% Neuronetics -19.62% -125.11% -22.15%

Does the media prefer SIBN or STIM?

In the previous week, Neuronetics had 1 more articles in the media than SiBone. MarketBeat recorded 2 mentions for Neuronetics and 1 mentions for SiBone. SiBone's average media sentiment score of 0.00 equaled Neuronetics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neuronetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate STIM or NNNN?

Neuronetics presently has a consensus price target of $4.67, suggesting a potential upside of 62.04%. Given Neuronetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Neuronetics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, STIM or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than Neuronetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $149.16M 1.47 -$39M -$0.44 N/A Anbio Biotechnology $8.65M 100.84 $6.40M N/A N/A

Is VREX or STIM more profitable?

Varex Imaging has a net margin of 2.55% compared to Neuronetics' net margin of -19.62%. Varex Imaging's return on equity of 9.19% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Varex Imaging 2.55% 9.19% 4.13% Neuronetics -19.62% -125.11% -22.15%

Does the media favor VREX or STIM?

In the previous week, Neuronetics had 1 more articles in the media than Varex Imaging. MarketBeat recorded 2 mentions for Neuronetics and 1 mentions for Varex Imaging. Varex Imaging's average media sentiment score of 0.86 beat Neuronetics' score of 0.00 indicating that Varex Imaging is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Varex Imaging 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuronetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Neuronetics (STIM) Competitors

$2.88 -0.03 (-1.03%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.82 -0.06 (-2.22%)

As of 04:21 AM Eastern

Compare

STIM vs. INMD, AVR, SIBN, NNNN, and VREX

Should you buy Neuronetics stock or one of its competitors? Neuronetics's main competitors and comparable companies include InMode (INMD), Anteris Technologies Global (AVR), SiBone (SIBN), Anbio Biotechnology (NNNN), and Varex Imaging (VREX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Neuronetics compare to InMode?

Neuronetics (NASDAQ:STIM) and InMode (NASDAQ:INMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Neuronetics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, InMode has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market.

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 8.4% of Neuronetics shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

InMode has a net margin of 20.69% compared to Neuronetics' net margin of -19.62%. InMode's return on equity of 11.99% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
InMode	20.69%	11.99%	10.60%

InMode has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.47	-$39M	-$0.44	N/A
InMode	$370.49M	2.20	$93.83M	$1.23	11.54

Neuronetics currently has a consensus price target of $4.67, suggesting a potential upside of 62.04%. InMode has a consensus price target of $16.00, suggesting a potential upside of 12.76%. Given Neuronetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Neuronetics is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Neuronetics and Neuronetics both had 2 articles in the media. InMode's average media sentiment score of 0.31 beat Neuronetics' score of 0.00 indicating that InMode is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMode	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InMode beats Neuronetics on 11 of the 15 factors compared between the two stocks.

How does Neuronetics compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Neuronetics has a net margin of -19.62% compared to Anteris Technologies Global's net margin of -4,619.27%. Anteris Technologies Global's return on equity of -77.69% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-4,619.27%	-77.69%	-67.99%
Neuronetics	-19.62%	-125.11%	-22.15%

53.6% of Neuronetics shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by company insiders. Comparatively, 8.4% of Neuronetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anteris Technologies Global presently has a consensus target price of $16.00, suggesting a potential upside of 109.97%. Neuronetics has a consensus target price of $4.67, suggesting a potential upside of 62.04%. Given Anteris Technologies Global's higher possible upside, equities research analysts plainly believe Anteris Technologies Global is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Anteris Technologies Global had 1 more articles in the media than Neuronetics. MarketBeat recorded 3 mentions for Anteris Technologies Global and 2 mentions for Neuronetics. Anteris Technologies Global's average media sentiment score of 0.70 beat Neuronetics' score of 0.00 indicating that Anteris Technologies Global is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anteris Technologies Global	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuronetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anteris Technologies Global has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Neuronetics has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Neuronetics has higher revenue and earnings than Anteris Technologies Global. Neuronetics is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	388.82	-$94.14M	-$1.95	N/A
Neuronetics	$149.16M	1.47	-$39M	-$0.44	N/A

Summary

Anteris Technologies Global and Neuronetics tied by winning 7 of the 14 factors compared between the two stocks.

How does Neuronetics compare to SiBone?

SiBone (NASDAQ:SIBN) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

SiBone has a net margin of -6.85% compared to Neuronetics' net margin of -19.62%. SiBone's return on equity of -8.23% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
Neuronetics	-19.62%	-125.11%	-22.15%

98.1% of SiBone shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 4.0% of SiBone shares are owned by insiders. Comparatively, 8.4% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SiBone has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Neuronetics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

In the previous week, Neuronetics had 1 more articles in the media than SiBone. MarketBeat recorded 2 mentions for Neuronetics and 1 mentions for SiBone. SiBone's average media sentiment score of 0.00 equaled Neuronetics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neuronetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SiBone has higher revenue and earnings than Neuronetics. SiBone is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$213.60M	3.86	-$18.90M	-$0.34	N/A
Neuronetics	$149.16M	1.47	-$39M	-$0.44	N/A

SiBone presently has a consensus target price of $24.17, indicating a potential upside of 29.93%. Neuronetics has a consensus target price of $4.67, indicating a potential upside of 62.04%. Given Neuronetics' higher probable upside, analysts plainly believe Neuronetics is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

SiBone beats Neuronetics on 10 of the 15 factors compared between the two stocks.

How does Neuronetics compare to Anbio Biotechnology?

Neuronetics (NASDAQ:STIM) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Anbio Biotechnology has lower revenue, but higher earnings than Neuronetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.47	-$39M	-$0.44	N/A
Anbio Biotechnology	$8.65M	100.84	$6.40M	N/A	N/A

Neuronetics presently has a consensus price target of $4.67, suggesting a potential upside of 62.04%. Given Neuronetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Neuronetics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

53.6% of Neuronetics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Neuronetics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.17, meaning that its share price is 417% more volatile than the broader market.

Anbio Biotechnology has a net margin of 0.00% compared to Neuronetics' net margin of -19.62%. Anbio Biotechnology's return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
Anbio Biotechnology	N/A	N/A	N/A

In the previous week, Neuronetics had 2 more articles in the media than Anbio Biotechnology. MarketBeat recorded 2 mentions for Neuronetics and 0 mentions for Anbio Biotechnology. Neuronetics' average media sentiment score of 0.00 equaled Anbio Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Neuronetics	Neutral
Anbio Biotechnology	Neutral

Summary

Neuronetics beats Anbio Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Neuronetics compare to Varex Imaging?

Varex Imaging (NASDAQ:VREX) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, Neuronetics had 1 more articles in the media than Varex Imaging. MarketBeat recorded 2 mentions for Neuronetics and 1 mentions for Varex Imaging. Varex Imaging's average media sentiment score of 0.86 beat Neuronetics' score of 0.00 indicating that Varex Imaging is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Varex Imaging	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuronetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Varex Imaging has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Neuronetics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Varex Imaging presently has a consensus target price of $16.88, suggesting a potential downside of 8.54%. Neuronetics has a consensus target price of $4.67, suggesting a potential upside of 62.04%. Given Neuronetics' stronger consensus rating and higher possible upside, analysts clearly believe Neuronetics is more favorable than Varex Imaging.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Varex Imaging	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

53.6% of Neuronetics shares are held by institutional investors. 4.6% of Varex Imaging shares are held by insiders. Comparatively, 8.4% of Neuronetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Neuronetics has lower revenue, but higher earnings than Varex Imaging. Neuronetics is trading at a lower price-to-earnings ratio than Varex Imaging, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Varex Imaging	$844.60M	0.92	-$70.30M	$0.52	35.48
Neuronetics	$149.16M	1.47	-$39M	-$0.44	N/A

Varex Imaging has a net margin of 2.55% compared to Neuronetics' net margin of -19.62%. Varex Imaging's return on equity of 9.19% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Varex Imaging	2.55%	9.19%	4.13%
Neuronetics	-19.62%	-125.11%	-22.15%

Summary

Neuronetics beats Varex Imaging on 9 of the 16 factors compared between the two stocks.

Get Neuronetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STIM vs. The Competition

Export

Metric	Neuronetics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$221.73M	$5.58B	$7.31B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-6.55	25.26	274.08	25.69
Price / Sales	1.47	71.56	638.21	78.99
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	7.58	5.78	10.47	6.32
Net Income	-$39M	$151.55M	$3.49B	$359.73M
7 Day Performance	-3.03%	-0.01%	-0.67%	0.17%
1 Month Performance	-0.35%	-3.53%	-3.17%	-3.27%
1 Year Performance	3.23%	6.37%	15.14%	5.58%

Neuronetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STIM Neuronetics	3.4622 of 5 stars	$2.88 -1.0%	$4.67 +62.0%	+4.7%	$221.73M	$149.16M	N/A	658
INMD InMode	1.9757 of 5 stars	$14.29 -1.7%	$16.00 +11.9%	-5.0%	$821.12M	$374.63M	11.61	660
AVR Anteris Technologies Global	2.5277 of 5 stars	$8.25 -2.0%	$16.00 +93.9%	+59.1%	$804.53M	$1.91M	N/A	174	Positive News
SIBN SiBone	2.1179 of 5 stars	$18.14 +0.5%	$24.17 +33.3%	+30.4%	$804.02M	$200.93M	N/A	376
NNNN Anbio Biotechnology	N/A	$5.50 -1.8%	N/A	N/A	$791.40M	$8.65M	N/A	27	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STIM) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neuronetics (STIM) Competitors

STIM vs. INMD, AVR, SIBN, NNNN, and VREX

How does Neuronetics compare to InMode?

Summary

How does Neuronetics compare to Anteris Technologies Global?

Summary

How does Neuronetics compare to SiBone?

Summary

How does Neuronetics compare to Anbio Biotechnology?

Summary

How does Neuronetics compare to Varex Imaging?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neuronetics (STIM) Competitors

STIM vs. INMD, AVR, SIBN, NNNN, and VREX

How does Neuronetics compare to InMode?

Which has more volatility and risk, STIM or INMD?

Do institutionals & insiders have more ownership in STIM or INMD?

Is STIM or INMD more profitable?

Which has higher valuation & earnings, STIM or INMD?

Do analysts recommend STIM or INMD?

Does the media prefer STIM or INMD?

Summary

How does Neuronetics compare to Anteris Technologies Global?

Is AVR or STIM more profitable?

Do insiders & institutionals have more ownership in AVR or STIM?

Do analysts prefer AVR or STIM?

Does the media favor AVR or STIM?

Which has more risk and volatility, AVR or STIM?

Which has stronger valuation & earnings, AVR or STIM?

Summary

How does Neuronetics compare to SiBone?

Is SIBN or STIM more profitable?

Do institutionals & insiders believe in SIBN or STIM?

Which has more volatility and risk, SIBN or STIM?

Does the media prefer SIBN or STIM?

Which has better earnings and valuation, SIBN or STIM?

Do analysts recommend SIBN or STIM?

Summary

How does Neuronetics compare to Anbio Biotechnology?

Which has stronger earnings & valuation, STIM or NNNN?

Do analysts rate STIM or NNNN?

Do institutionals and insiders hold more shares of STIM or NNNN?

Which has more volatility and risk, STIM or NNNN?

Is STIM or NNNN more profitable?

Does the media favor STIM or NNNN?

Summary

How does Neuronetics compare to Varex Imaging?

Does the media favor VREX or STIM?

Which has more risk and volatility, VREX or STIM?

Do analysts recommend VREX or STIM?

Do institutionals & insiders have more ownership in VREX or STIM?

Which has stronger valuation and earnings, VREX or STIM?

Is VREX or STIM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools